Orthocell partner receives US FDA clearance for marine-derived bone graft | Stockhead

Orthocell (ASX:OCC) strategic partner Marine Biomedical has received 510(k) FDA clearance for its PearlBone bone graft substitute.

Continue in Briflio to read, react, comment, and share.